Mindimmune Therapeutics, Inc.
Publicly observedKingston, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Kingston | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Mindimmune Therapeutics, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | DDPZS2FUTEK3 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant22 Sept 2026Publicly observed
NIH SBIR/STTR award: Targeting CD11c immune cells to alleviate cerebral amyloid angiopathy and amyloid-related imaging abnormality in patients with Alzheimer's disease
USD 496,415.00 · National Institute on Aging · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.